Immunotherapy Combo Shows Signs of Efficacy in 2 HCC Settings

Rita Colorito
Published: Monday, Oct 21, 2019
Anthony B. El-Khoueiry, MD

Anthony B. El-Khoueiry, MD

Using dual checkpoint inhibitors in patients with hepatocellular carcinoma (HCC) is demonstrating activity with a manageable safety profile in both second-line and perioperative settings, according to findings presented at the International Liver Cancer Association Annual Conference (ILCA 2019).

In updated data from the CheckMate-040 study, the combination of nivolumab (Opdivo), a PD-1 inhibitor, plus ipilimumab (Yervoy), a CTLA-4 inhibitor, demonstrated a favorable benefit–risk profile in patients previously treated with sorafenib (Nexavar).1 In patients with resectable HCC, use of the combination before surgery was associated with a pathologic complete response (pCR) rate of 29% in a phase II study.2

The findings add to the growing body of data about the immunotherapy duo, which has been approved for patients with unresectable or metastatic melanoma; intermediate- or poor-risk, previously untreated renal cell carcinoma; and microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer that has progressed after chemotherapy. In HCC, nivolumab monotherapy is approved for patients who have been previously treated with sorafenib.3

CheckMate-040 Findings in Advanced Disease

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication